Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 2/20 | 0.58 |
| ▸ | BRD9 | Q9H8M2 | 12/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.52 |
| ▸ | BRPF1 | P55201 | 3/20 | 0.52 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 3/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD4 | P21917 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1487941 | 0.86 | NCF1 (0.58) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL16573967 | 0.84 | LIPG (0.52) | NCF1BRD9BRD4 | |
| SCHEMBL415498 | 0.83 | BRD4 (0.48) | BRD9BRD4DRD2DRD3DRD4 | |
| SCHEMBL415624 | 0.83 | DRD2 (0.51) | NCF1BRD9BRD4ADRA2CDRD2 | |
| SCHEMBL3127155 | 0.83 | BRD4 (0.53) | BRD9BRD4 | |
| SCHEMBL14355870 | 0.82 | NCF1 (0.57) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL8361520 | 0.82 | DRD2 (0.72) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL16814964 | 0.81 | HTR1A (0.55) | NCF1BRD9DRD2DRD3HTR1A | |
| SCHEMBL416499 | 0.81 | KDM4E (0.41) | NCF1BRD9BRD4BRPF1BRD7 | |
| SCHEMBL22957823 | 0.80 | MEN1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2012-01-26 | — | — | US | disclosed |
| EP-2376431-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | LABORATOIRE BIODIM (FR) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010066847-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | CELLVIR (FR) | 2010-06-17 | — | — | WO | disclosed |
| EP-2196453-A1 | Novel substituted aryl derivatives, their process of preparation and their therapeutical uses as anti-HIV agents | Cellvir (FR) | 2010-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022054-A1 | NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS | HAVCR2, MAVS, EIF2AK2 | NCF1 750/4885BRD9 731/4885BRD4 244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.